Mycophenolate Mofetil Treatment for IgA Nephropathy: A Meta-Analysis | Zendy

Gaosi Xu | Zendy; Weiping Tu | Zendy; Dongfeng Jiang | Zendy; Chengyun Xu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mycophenolate Mofetil Treatment for IgA Nephropathy: A Meta-Analysis

Author(s) -

Gaosi Xu,

Weiping Tu,

Dongfeng Jiang,

Chengyun Xu

Publication year - 2008

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000168483

Subject(s) - medicine , nephropathy , cochrane library , meta analysis , randomized controlled trial , medline , proteinuria , placebo , glomerulonephritis , mycophenolate , clinical trial , transplantation , kidney , pathology , alternative medicine , diabetes mellitus , endocrinology , political science , law

Worldwide, IgA nephropathy (IgAN) is the most common type of glomerulonephritis. Mycophenolate mofetil (MMF) is relatively selective for lymphocytes and inhibits antibody production by B cells more than other immunosuppressants. Several randomized controlled trials (RCTs) have analyzed the role of MMF in patients with IgAN. We conducted this meta-analysis of all available RCTs to ascertain the benefits and risks of MMF treatment in comparison with placebos or steroids in patients with IgAN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research